Which priority intervention would the nurse take when admitting a client experiencing status asthmaticus?

Choice A rationale Administering a short-acting B2 agonist (SABA) such as albuterol is the priority intervention for status asthmaticus, a severe, life-threatening asthma exacerbation that is unresponsive to usual treatment. SABAs are potent bronchodilators that rapidly relax the bronchial smooth muscles by stimulating B2-adrenergic receptors, leading to immediate relief of acute bronchospasm and improving critical airflow. Choice B rationale While administering oxygen is a necessary supportive measure for a client experiencing hypoxemia during status asthmaticus, the immediate life-threatening problem is the severe airway obstruction, which must be addressed first to open the airways and allow the oxygen to reach the alveoli. The SABA (Choice A) addresses the root problem of bronchospasm most rapidly and effectively. Choice C rationale Administering a long-acting B2 agonist (LABA) is not appropriate for the acute management of status asthmaticus. LABAs, such as salmeterol, have a slow onset of action and are designed for long-term control and maintenance therapy of asthma, not for the immediate relief of a severe, acute exacerbation requiring rapid bronchodilation. Choice D rationale Administering intravenous corticosteroids (e.g., methylprednisolone) is a crucial intervention to reduce airway inflammation in status asthmaticus, but their therapeutic effects require several hours to become fully evident. Therefore, they are secondary to the immediate life-saving bronchodilation provided by the inhaled short-acting B2 agonist (Choice A).